JP6054876B2 - アデノウイルス血清型２６および血清型３５のフィロウイルスワクチン - Google Patents

アデノウイルス血清型２６および血清型３５のフィロウイルスワクチン Download PDF

Info

Publication number
JP6054876B2
JP6054876B2 JP2013544747A JP2013544747A JP6054876B2 JP 6054876 B2 JP6054876 B2 JP 6054876B2 JP 2013544747 A JP2013544747 A JP 2013544747A JP 2013544747 A JP2013544747 A JP 2013544747A JP 6054876 B2 JP6054876 B2 JP 6054876B2
Authority
JP
Japan
Prior art keywords
vector
adenoviral vector
vectors
rad35
vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2013544747A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014503206A5 (enExample
JP2014503206A (ja
Inventor
ジェー サリバン ナンシー
ジェー サリバン ナンシー
ジェー ネーブル ゲイリー
ジェー ネーブル ゲイリー
アシドゥ クレモン
アシドゥ クレモン
チェン チェン
チェン チェン
グラッツィア パウ マリア
グラッツィア パウ マリア
ハウトスミット ヤープ
ハウトスミット ヤープ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Goverment Of United States, Represented By Secretary Of Department Of Health And Human Services AS
US Department of Health and Human Services
Original Assignee
Goverment Of United States, Represented By Secretary Of Department Of Health And Human Services AS
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Goverment Of United States, Represented By Secretary Of Department Of Health And Human Services AS, US Department of Health and Human Services filed Critical Goverment Of United States, Represented By Secretary Of Department Of Health And Human Services AS
Publication of JP2014503206A publication Critical patent/JP2014503206A/ja
Publication of JP2014503206A5 publication Critical patent/JP2014503206A5/ja
Application granted granted Critical
Publication of JP6054876B2 publication Critical patent/JP6054876B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/235—Adenoviridae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/14011—Filoviridae
    • C12N2760/14034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/14011—Filoviridae
    • C12N2760/14111—Ebolavirus, e.g. Zaire ebolavirus
    • C12N2760/14134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2013544747A 2010-12-14 2011-12-14 アデノウイルス血清型２６および血清型３５のフィロウイルスワクチン Active JP6054876B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42295410P 2010-12-14 2010-12-14
US61/422,954 2010-12-14
PCT/US2011/064944 WO2012082918A1 (en) 2010-12-14 2011-12-14 Adenovirus serotype 26 and serotype 35 filovirus vaccines

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016206679A Division JP6268258B2 (ja) 2010-12-14 2016-10-21 アデノウイルス血清型２６および血清型３５のフィロウイルスワクチン

Publications (3)

Publication Number Publication Date
JP2014503206A JP2014503206A (ja) 2014-02-13
JP2014503206A5 JP2014503206A5 (enExample) 2015-01-29
JP6054876B2 true JP6054876B2 (ja) 2016-12-27

Family

ID=46245095

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013544747A Active JP6054876B2 (ja) 2010-12-14 2011-12-14 アデノウイルス血清型２６および血清型３５のフィロウイルスワクチン
JP2016206679A Active JP6268258B2 (ja) 2010-12-14 2016-10-21 アデノウイルス血清型２６および血清型３５のフィロウイルスワクチン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016206679A Active JP6268258B2 (ja) 2010-12-14 2016-10-21 アデノウイルス血清型２６および血清型３５のフィロウイルスワクチン

Country Status (14)

Country Link
US (1) US9701718B2 (enExample)
EP (1) EP2655604B1 (enExample)
JP (2) JP6054876B2 (enExample)
KR (1) KR101879892B1 (enExample)
CN (1) CN103370411B (enExample)
AU (1) AU2011343798B2 (enExample)
BR (1) BR112013014712B1 (enExample)
CA (1) CA2821289C (enExample)
DK (1) DK2655604T3 (enExample)
EA (1) EA029504B1 (enExample)
ES (1) ES2676196T3 (enExample)
PL (1) PL2655604T3 (enExample)
WO (1) WO2012082918A1 (enExample)
ZA (1) ZA201304260B (enExample)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9701718B2 (en) 2010-12-14 2017-07-11 Janssen Vaccines & Prevention B.V. Adenovirus serotype 26 and serotype 35 filovirus vaccines
EA035530B1 (ru) 2014-06-26 2020-06-30 Янссен Вэксинс Энд Превеншн Б.В. Антитела и антигенсвязывающие фрагменты, которые специфично связываются с белком тау, ассоциированным с микротрубочками
ZA201608812B (en) 2014-06-26 2019-08-28 Janssen Vaccines & Prevention Bv Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
JP6462861B2 (ja) 2014-09-03 2019-01-30 バヴァリアン ノルディック エー／エス フィロウイルス感染に対する防御免疫の誘導を目的とする方法及び組成物
KR20190062617A (ko) 2014-09-03 2019-06-05 버베리안 노딕 에이/에스 면역 반응을 증대시키기 위한 방법 및 조성물
DK3197489T3 (da) 2014-09-26 2021-04-19 Beth Israel Deaconess Medical Ct Inc Fremgangsmåder og sammensætninger til at fremkalde beskyttende immunitet over for human immundefekt virusinfektion
SI3271729T1 (sl) 2015-03-18 2021-04-30 Janssen Vaccines & Prevention B.V. Testi za rekombinantne ekspresijske sisteme
MA55825A (fr) 2015-12-15 2022-03-09 Janssen Vaccines & Prevention Bv Antigènes, vecteurs, compositions du virus de l'immunodéficience humaine et leurs procédés d'utilisation
MX2018009997A (es) 2016-02-18 2019-02-07 Int Flavors & Fragrances Inc Composiciones de cápsulas de poliurea.
EP3429740B1 (en) 2016-03-18 2021-05-05 International Flavors & Fragrances Inc. Silica microcapsules and methods of preparing same
BR112018075785A2 (pt) 2016-06-16 2019-04-02 Janssen Vaccines & Prevention B.V. formulação de vacina para o hiv
WO2018006089A1 (en) 2016-07-01 2018-01-04 International Flavors & Fragrances Inc. Stable microcapsule compositions
WO2018011198A1 (en) 2016-07-15 2018-01-18 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against a marburg virus infection
US10925956B2 (en) 2016-07-15 2021-02-23 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against a marburg virus infection
CN116764558A (zh) 2016-09-16 2023-09-19 国际香料和香精公司 用粘度控制剂稳定的微胶囊组合物
US20180085291A1 (en) 2016-09-28 2018-03-29 International Flavors & Fragrances Inc. Microcapsule compositions containing amino silicone
US11173204B2 (en) 2017-04-06 2021-11-16 Janssen Vaccines & Prevention B.V. MVA-BN and Ad26.ZEBOV or Ad26.filo prime-boost regimen
US20180346648A1 (en) 2017-05-30 2018-12-06 International Flavors & Fragrances Inc. Branched polyethyleneimine microcapsules
CA3066573A1 (en) 2017-06-15 2018-12-20 Janssen Vaccines & Prevention B.V. Poxvirus vectors encoding hiv antigens, and methods of use thereof
WO2019018724A1 (en) 2017-07-21 2019-01-24 Janssen Vaccines & Prevention B.V. METHODS FOR SAFE INDUCTION OF MULTICLADED CROSS-IMMUNITY AGAINST HUMAN IMMUNODEFICIENCY VIRUS INFECTION IN HUMAN BEINGS
SG11202000019RA (en) * 2017-07-28 2020-02-27 Janssen Vaccines & Prevention Bv Methods and compositions for heterologous reprna immunizations
US10864263B2 (en) 2017-11-20 2020-12-15 Janssen Pharmaceuticals, Inc. Method of providing safe administration of adenoviral vectors encoding a zika virus antigen
SG11202005710YA (en) 2017-12-19 2020-07-29 Janssen Sciences Ireland Unlimited Co Methods and compositions for inducing an immune response against hepatitis b virus (hbv)
WO2019210125A1 (en) 2018-04-27 2019-10-31 International Flavors & Fragrances Inc. Stable polyurea microcapsule compositions
US11713469B2 (en) 2018-07-20 2023-08-01 Janssen Vaccines & Prevention B.V. Recombinant adenoviral vector expressing Zika antigen with improved productivity
WO2020064621A1 (en) 2018-09-25 2020-04-02 Janssen Vaccines & Prevention B.V. Method of inducing an immune response against human immunodeficiency virus by co-localized administration of vaccine components
WO2020131956A1 (en) 2018-12-18 2020-06-25 International Flavors & Fragrances Inc. Hydroxyethyl cellulose microcapsules
BR112021022528A2 (pt) 2019-05-14 2021-12-28 Janssen Biotech Inc Remoção eficiente de impurezas usando um processo de diafiltração
EP4097122A4 (en) 2020-01-31 2024-07-17 Beth Israel Deaconess Medical Center, Inc. COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING CORONAVIRUS INFECTION - SARS-COV-2 VACCINES
EP4150061A1 (en) 2020-05-11 2023-03-22 Janssen Pharmaceuticals, Inc. Stabilized coronavirus spike protein fusion proteins
KR20230028517A (ko) 2020-06-29 2023-02-28 얀센 백신스 앤드 프리벤션 비.브이. 호흡기 세포융합 바이러스 감염에 대한 백신 조합물
AU2021303722A1 (en) 2020-07-06 2022-12-15 Janssen Pharmaceuticals, Inc. Stabilized Corona virus spike protein fusion proteins
WO2022008613A1 (en) 2020-07-08 2022-01-13 Janssen Sciences Ireland Unlimited Company Rna replicon vaccines against hbv
CN114845733A (zh) * 2020-08-22 2022-08-02 俄罗斯联邦卫生部的联邦国家预算机构“以名誉院士N.F.加马列亚命名的国家流行病学和微生物学研究中心” 抗严重急性呼吸综合征病毒SARS-CoV-2的表达载体
WO2022175479A1 (en) 2021-02-19 2022-08-25 Janssen Vaccines & Prevention B.V. Vaccine combinations against respiratory syncytial virus strain a and b infections
AU2022221983A1 (en) 2021-02-19 2023-08-17 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv fb antigens
AU2022249741A1 (en) 2021-04-01 2023-09-21 Msd International Business Gmbh Stabilized pre-fusion piv3 f proteins
EP4124383A1 (en) 2021-07-27 2023-02-01 International Flavors & Fragrances Inc. Biodegradable microcapsules
WO2023020939A1 (en) 2021-08-17 2023-02-23 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines
WO2023026182A1 (en) 2021-08-24 2023-03-02 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines
EP4154974A1 (en) 2021-09-23 2023-03-29 International Flavors & Fragrances Inc. Biodegradable microcapsules
WO2023047349A1 (en) 2021-09-24 2023-03-30 Janssen Pharmaceuticals, Inc. Stabilized coronavirus spike protein fusion proteins
WO2023047348A1 (en) 2021-09-24 2023-03-30 Janssen Pharmaceuticals, Inc. Stabilized corona virus spike protein fusion proteins
WO2023111725A1 (en) 2021-12-14 2023-06-22 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines
WO2023110618A1 (en) 2021-12-16 2023-06-22 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion hmpv fusion proteins
WO2023198815A1 (en) 2022-04-14 2023-10-19 Janssen Vaccines & Prevention B.V. Sequential administration of adenoviruses
EP4590689A1 (en) 2022-09-23 2025-07-30 Janssen Vaccines & Prevention B.V. Stabilized trimeric class i fusion proteins
EP4590690A1 (en) 2022-09-23 2025-07-30 Janssen Vaccines & Prevention B.V. Pre-fusion human piv1 f proteins
WO2024061759A1 (en) 2022-09-23 2024-03-28 Janssen Vaccines & Prevention B.V. Stabilized coronavirus s proteins
CN120344553A (zh) 2022-10-06 2025-07-18 Msd国际商务股份有限公司 稳定的融合前piv3 f蛋白
EP4406641A1 (en) 2023-01-26 2024-07-31 International Flavors & Fragrances Inc. Biodegradable microcapsules containing low log p fragrance

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6852324B1 (en) * 1997-12-23 2005-02-08 The United States Of America As Represented By The Department Of Health And Human Services Immunization for ebola virus infection
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
CA2776272C (en) 2001-10-01 2016-05-17 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Development of a preventive vaccine for filovirus infection in primates
WO2004001032A2 (en) 2002-04-25 2003-12-31 Crucell Holland B.V. Stable adenoviral vectors and methods for propagation thereof
KR101021387B1 (ko) 2002-04-25 2011-03-14 크루셀 홀란드 비.브이. 아데노바이러스 벡터를 생산하기 위한 수단 및 방법
AU2003288273A1 (en) * 2002-10-23 2004-05-13 Crucell Holland B.V. New settings for recombinant adenoviral-based vaccines
DK1654370T3 (en) * 2003-08-01 2018-08-20 Government Of The Us Secretary Department Of Health And Human Services ACCELERATED EBOLA VACCINATION
WO2006037038A1 (en) 2004-09-27 2006-04-06 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Optimized vaccines to provide protection against ebola and other viruses
KR101253363B1 (ko) 2004-10-13 2013-04-15 베쓰 이스라엘 디코니스 메디칼 센터 인크 개선된 아데노바이러스 벡터 및 그것의 용도
CN101072879B (zh) * 2004-10-13 2011-05-11 克鲁塞尔荷兰公司 改良的腺病毒载体及其应用
SI1802336T1 (sl) * 2004-10-14 2012-01-31 Crucell Holland Bv Začetna/obnovitvena cepiva proti malariji
WO2007104792A2 (en) * 2006-03-16 2007-09-20 Crucell Holland B.V. Recombinant adenoviruses based on serotype 26 and 48, and use thereof
US20090110695A1 (en) * 2006-03-27 2009-04-30 Menzo Jans Emko Havenga Compositions Comprising a Recombinant Adenovirus and an Adjuvant
WO2009092113A2 (en) * 2008-01-19 2009-07-23 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions for the delivery of vaccines to disrupted epithelium
US9701718B2 (en) 2010-12-14 2017-07-11 Janssen Vaccines & Prevention B.V. Adenovirus serotype 26 and serotype 35 filovirus vaccines

Also Published As

Publication number Publication date
CN103370411A (zh) 2013-10-23
CN103370411B (zh) 2016-05-04
ZA201304260B (en) 2021-05-26
US20140017278A1 (en) 2014-01-16
CA2821289C (en) 2019-05-21
KR20140019304A (ko) 2014-02-14
US9701718B2 (en) 2017-07-11
KR101879892B1 (ko) 2018-08-17
EA029504B1 (ru) 2018-04-30
EA201390866A1 (ru) 2014-05-30
BR112013014712A2 (pt) 2017-06-06
AU2011343798B2 (en) 2016-07-14
EP2655604A4 (en) 2015-01-28
JP2014503206A (ja) 2014-02-13
ES2676196T3 (es) 2018-07-17
WO2012082918A1 (en) 2012-06-21
AU2011343798A1 (en) 2013-07-11
JP6268258B2 (ja) 2018-01-24
JP2017048207A (ja) 2017-03-09
PL2655604T3 (pl) 2019-02-28
EP2655604A1 (en) 2013-10-30
CA2821289A1 (en) 2012-06-21
DK2655604T3 (en) 2018-08-06
EP2655604B1 (en) 2018-05-09
BR112013014712B1 (pt) 2021-03-02

Similar Documents

Publication Publication Date Title
JP6054876B2 (ja) アデノウイルス血清型２６および血清型３５のフィロウイルスワクチン
US11913013B2 (en) Chimpanzee adenoviral vector-based filovirus vaccines
Geisbert et al. Recombinant adenovirus serotype 26 (Ad26) and Ad35 vaccine vectors bypass immunity to Ad5 and protect nonhuman primates against ebolavirus challenge
AU2015311868B2 (en) Methods and compositions for enhancing immune responses
CN107454848B (zh) 用于诱导针对丝状病毒感染的保护性免疫的方法和组合物
JP5046941B2 (ja) エボラ及び他のウイルスに対する防御に最適化されたワクチン
WO2016187613A1 (en) Methods and compositions for inducing protective immunity against filovirus infection and/or disease
US10925955B2 (en) Methods and compositions for inducing protective immunity against a Marburg virus infection
OA19216A (en) Methods and compositions for inducing protective immunity against a Marburg virus infection.
HK1239544A1 (en) Methods and compositions for inducing protective immunity against filovirus infection
HK1239544B (en) Methods and compositions for inducing protective immunity against filovirus infection

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141208

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20141208

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20160216

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160621

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161021

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20161021

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20161111

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20161129

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20161201

R150 Certificate of patent or registration of utility model

Ref document number: 6054876

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250